Evidence map›Paper›PMID 35090175›Full record

Trial reportThe Journal of infectious diseases2023

Efficacy of a Carrageenan Gel in Increasing Clearance of Anal Human Papillomavirus Infections in Men: Interim Analysis of a Double-Blind, Randomized Controlled Trial.

Cassandra Laurie, Mariam El-Zein, Joseph Tota, Farzin Khosrow-Khavar, Pierre-Paul Tellier, François Coutlée, Alexandra de Pokomandy, Eduardo L Franco, Lubricant Investigation in Men to Inhibit Transmission of Human Papillomavirus Infection (LIMIT-HPV) Study Group

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02354144 (A Randomized Controlled Trial of a Carrageenan-Containing Lubricant to Reduce Transmission of Human Papillomavirus Infection Among Men Who Have Sex With Men), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02354144 phase2 / phase3terminatednot on this map

A Randomized Controlled Trial of a Carrageenan-Containing Lubricant to Reduce Transmission of Human Papillomavirus Infection Among Men Who Have Sex With Men

TypeinterventionalSponsorMcGill UniversityRan2016 to 2020Enrolled258ConditionsHuman Papillomavirus InfectionArmsCarrageenan-based gel, Control gel
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Cassandra LaurieDivision of Cancer Epidemiology, McGill University, Montreal, Canada.
Mariam El-ZeinDivision of Cancer Epidemiology, McGill University, Montreal, Canada.ORCID 0000-0002-5190-0370
Joseph TotaDivision of Cancer Epidemiology, McGill University, Montreal, Canada.
Farzin Khosrow-KhavarDivision of Cancer Epidemiology, McGill University, Montreal, Canada.
Pierre-Paul TellierDepartment of Family Medicine, McGill University, Montreal, Canada.
François CoutléeLaboratoire de virologie moléculaire, Centre de recherche, Centre hospitalier de l'Université de Montréal, et Département de Microbiologie, infectiologie et immunologie, Université de Montréal, Montreal, Canada.
Alexandra de PokomandyDepartment of Family Medicine, McGill University, Montreal, Canada.
Eduardo L FrancoDivision of Cancer Epidemiology, McGill University, Montreal, Canada.
Lubricant Investigation in Men to Inhibit Transmission of Human Papillomavirus Infection (LIMIT-HPV) Study Group
McGill University · CACentre Hospitalier de l’Université de Montréal · CAMcGill University Health Centre · CA

Funding

CIHR FDN-143347CIHR MOP-137066
6 · The paper itself

Abstract

Preclinical studies have demonstrated carrageenan's anti-human papillomavirus (HPV) activity. We assessed efficacy of a carrageenan-based gel compared to a placebo gel in increasing the clearance of anal HPV infections among gay, bisexual, and other men who have sex with men (gbMSM). Of 255 enrolled gbMSM, 134 were HPV positive at baseline and had valid HPV results for ≥2 visits. Carrageenan did not differ from placebo in clearing all baseline infections (hazard ratio, 0.84 [95% confidence interval, .31-2.27]), based on having 2 consecutive HPV-negative visits following at least 1 HPV-positive visit. There were no remarkable differences for analyses at the HPV type level or by human immunodeficiency virus status. CLINICAL TRIALS REGISTRATION: NCT02354144.

Indexed as

HIV InfectionsPapillomavirus InfectionsSexual and Gender MinoritiesAnal CanalCarrageenanHomosexuality, MaleHuman Papillomavirus VirusesHumansMalePapillomaviridaeCarrageenanand other men who have sex with menbisexualcarrageenangaygelHIVHPVhuman papillomavirusmen who have sex with menmicrobiciderandomized controlled trial

Identifiers

PMID35090175
PMCPMC9891427
OpenAlexW4210514078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.